Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Progyny Inc Market Cap
Based on ratings from 5 stock analysts, the Progyny Inc stock price is expected to increase by 13.78% in 12 months. This is calculated by using the average 12-month stock price forecast for Progyny Inc. The lowest target is $43.00 and the highest is $49.00. Please note analyst price targets are not guaranteed and could be missed completely.
About 5 Wall Street analysts have assignedPGNY 5 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Progyny Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on PGNY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| jailendra singh Truist Financial | Buy | $47.0 | maintained | Jan 4, 2024 |
| stephanie davis Barclays | Buy | $48.0 | initiatedcoverage | Jan 2, 2024 |
| david larsen BTIG | Buy | $45.0 | maintained | Dec 28, 2023 |
| glen santangelo Jefferies | Buy | $43.0 | reiterated | Nov 30, 2023 |
| anne samuel J.P. Morgan | Buy | $49.0 | rated | Nov 20, 2023 |
| scott schoenhaus KeyBanc | Buy | $45.0 | maintained | Nov 8, 2023 |
| allen lutz Bank of America Securities | Buy | $47.0 | reiterated | Nov 8, 2023 |
| richard close Canaccord Genuity | Buy | $46.0 | maintained | Nov 7, 2023 |
| michael cherny Bank of America Securities | Buy | $51.0 | reiterated | Aug 4, 2023 |
| sarah james Cantor Fitzgerald | Buy | $45.0 | maintained | May 9, 2023 |
| dev weerasuriya Berenberg Bank | Buy | $55.0 | initiatedcoverage | Nov 18, 2022 |
| iris long Berenberg Bank | Buy | $80.0 | reiterated | Nov 5, 2021 |
| stephen tanal SVB Securities | Buy | $50.0 | maintained | Nov 6, 2020 |
| daniel grosslight Citigroup | Buy | $28.0 | initiatedcoverage | Nov 19, 2019 |
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
When did it IPO
2019
Staff Count
393
Country
United States
Sector/Industry
Healthcare/Health Information Services
CEO
Mr. Peter Anevski
Market Cap
$3.91B
In 2023, PGNY generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PGNY's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
EXPO-USD
$76.86
LOPE-USD
$130.07
AXSM-USD
$80.47
LNTH-USD
$57.46
COLB-USD
$18.28
NEOG-USD
$17.64
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
